UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): ~~April 29~~May 3, 2022

ZOSANO PHARMA CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	001-36570	45-4488360
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
(State or other jurisdictionof incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

34790 Ardentech Court

Fremont, CA 94555

(Address of principal executive offices) (Zip Code)

(510) 745-1200

(Registrant’s telephone number, include area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class		~~Trading Symbol~~TradingSymbol		Name of each ~~exchange~~exchangeon on which registered
Common Stock, $0.0001 par value		ZSAN		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 85.0102 ~~Other~~Departure ~~Events~~of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On ~~April~~May 293, 2022, Steven A. Elms tendered his resignation as a director of the board of directors (the “Board”) of Zosano Pharma Corporation ~~issued~~(the “Company”) and as a ~~press~~member ~~release~~of ~~providing~~the acompensation ~~corporate~~and ~~update.~~nominating Aand ~~copy~~corporate governance committees of the ~~press~~Board, ~~release~~effective immediately. Mr. Elms’ resignation is ~~attached~~not asbased ~~Exhibit~~on ~~99.1~~any todisagreement ~~this~~with ~~Current~~the ~~Report~~Company on ~~Form~~any ~~8-K~~matter ~~and~~relating isto ~~incorporated~~the byCompany’s ~~reference~~operations, ~~herein~~policies or practice.

Following Mr. Elms’ resignation, on May 3, 2022, pursuant to the authority contained in the Company’s amended and restated certificate of incorporation, the Board approved decreasing the size of the Board to six members.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

		Description
99.1		Press Release dated April 29, 2022, titled “Zosano Pharma Provides Corporate Update”
104.1		Cover Page Interactive Data File (embedded within the Inline XBRL document)


		Description

104.1		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 29, 2022

ZOSANO PHARMA CORPORATION

Date: May 5, 2022

ZOSANO PHARMA CORPORATION

/s/ Christine Matthews

Christine Matthews

Chief Financial Officer

Filing Compare · Zosano Pharma Corp